The OncoMasTR Test Predicts Distant Recurrence in ER-Positive, HER2-Negative Early-Stage Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8
Clin. Cancer Res 2021 Aug 11;[EPub Ahead of Print], M Filipits, M Rudas, V Kainz, CF Singer, F Fitzal, Z Bago-Horvath, R Greil, M Balic, P Regitnig, S Halper, W Hulla, D Egle, S Barron, T Loughman, D O'Leary, WM Gallagher, D Hlauschek, M Gnant, P DubskyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.